AMG 160 bei mCRPC am ESMO 2020
Präsentation der Interimsresultate der Dosisfindung in der laufenden Phase I Studie des PSMA x CD3 BiTE AMG 160 bei mCRPC.
Präsentation der Interimsresultate der Dosisfindung in der laufenden Phase I Studie des PSMA x CD3 BiTE AMG 160 bei mCRPC.
You are now leaving oncologyhorizons.at
Amgen does not endorse or accept liability for sites controlled by third parties
You are now leaving oncologyhorizons.at
Amgen does not endorse or accept liability for sites controlled by third parties
You are now leaving oncologyhorizons.at
Amgen does not endorse or accept liability for sites controlled by third parties